KURA

Kura Oncology, Inc.

9.91 USD

Last updated Dec 3, 05:06 UTC

Yesterday HIGH

$9.98

Yesterday LOW

$9.18

52w HIGH

$16.14

52w LOW

$7.41

EPS

-0.5

PE

-19.82

Next Earnings

Feb 22, 2024

Overview News Government Trades

Kura Oncology, Inc. stock is up 9.99% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 December’s closed higher than November. 100% of analysts rate it a buy.

Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

San Diego, United States Of America

Website

kuraoncology.com

richadhand@benzinga.com

Fri Aug 11, 2023

B of A Securities Initiates Coverage On Kura Oncology with Buy Rating, Announces Price Target of $31

B of A Securities analyst Jason Zemansky initiates coverage on Kura Oncology (NASDAQ:KURA) with a Buy rating and announces Price Target of $31.
Lisa Levin

Fri Aug 4, 2023

Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.
totan@benzinga.com

Thu Aug 3, 2023

Kura Oncology Q2 EPS $(0.53) Beats $(0.57) Estimate

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.57) by 7.02 percent. This is a 1.92 percent decrease over losses of $(0.52) per share from the
Benzinga Insights

Thu Aug 3, 2023

Earnings Scheduled For August 3, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Benzinga Insights

Thu Jul 27, 2023

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
richadhand@benzinga.com

Thu Jul 27, 2023

Scotiabank Initiates Coverage On Kura Oncology with Sector Perform Rating, Announces Price Target of $10.5

Scotiabank analyst George Farmer initiates coverage on Kura Oncology (NASDAQ:KURA) with a Sector Perform rating and announces Price Target of $10.5.
Benzinga Insights

Fri Jul 21, 2023

Where Kura Oncology Stands With Analysts
richadhand@benzinga.com

Fri Jul 21, 2023

Cantor Fitzgerald Reiterates Overweight on Kura Oncology, Maintains $30 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) with a Overweight and maintains $30 price target.
Lisa Levin

Thu Jun 22, 2023

Over $27M Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying

Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Lisa Levin

Wed Jun 14, 2023

Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial intelligence.